Senior Manager, SG&A Accounting
Corcept Therapeutics
Summary
As the Senior Manager, SG&A Accounting, you will help lead SG&A accounting operations and be a strategic business partner for over 40 departments. This position will report to the Director of Accounting and will manage/mentor accounting analysts. You will have the opportunity to lead projects that shape the Finance organization and Corcept overall as we continue to grow.
Job description
Responsibilities
- Full ownership of managing the financial close for SG&A related activities in accordance with GAAP to ensure the accuracy and integrity of financial data
- Lead day-to-day SG&A accounting operations, including general ledger management, journal entry preparation and review, account reconciliation and close support
- Support accounting coverage for more than 40 departments, serving as a reliable finance partner to business stakeholders
- Drive end-to-end coordination of projects and system/process improvements to keep the accounting team current, scalable, and able to support a growing SG&A organization
- Manage and mentor one or more accountants, cultivating talent, delegating ownership, and showcasing the team's achievements to stakeholders
- Review, interpret, and apply consistent accounting treatment for a wide range of contracts, including consulting and professional services, subscriptions and SaaS tools, milestone-based agreements, medical grants and sponsorships, conference and marketing agreements, and analytical and research services
- Build and sustain trusted partnerships with SG&A leaders, serving as the primary accounting advisor for operational and financial decision-making
- Assess proper accounting treatment (expense vs. prepaid vs. capitalization) with clear rationale and documentation
- Review invoices to ensure expenses are accurately recorded into the accounting system
- Help prepare quarterly reviews and year-end audits and periodic reports to the SEC
- Continually drive process improvements for greater efficiency and timeliness
Preferred Skills, Qualifications and Technical Proficiencies
- Maintain a strong sense of work accountability and is a self-starter
- Strong project management capabilities, with a track record of successfully leading and executing complex initiatives; able to effectively manage and prioritize multiple tasks and work with tight deadlines
- Exceptional critical thinking and problem-solving abilities, enabling effective solutions for complex challenges
- Adept at identifying process inefficiencies, creating practical solutions, and driving continuous improvements
Preferred Education and Experience
- Requires a Bachelor's Degree in Accounting or Finance
- At least 8 years of relevant work experience in accounting management
- Experience in biotech/pharmaceutical environment is preferred
- CPA with Big 4 experience is a strong plus
- Knowledge of/exposure to Netsuite accounting system is a strong plus
Requirements
- Bachelor's Degree in Accounting or Finance
- At least 8 years of relevant work experience in accounting management
- Experience in biotech/pharmaceutical environment preferred
- CPA with Big 4 experience a strong plus
- Knowledge of/exposure to Netsuite accounting system a strong plus
- Strong project management capabilities
- Exceptional critical thinking and problem-solving abilities
- Strong sense of work accountability and self-starter
- Adept at identifying process inefficiencies and driving continuous improvements
- Must be currently authorized to work in the United States on a full-time basis
Company overview
Corcept Therapeutics Inc. is a commercial-stage pharmaceutical company founded in 1998 and headquartered in Redwood City, California. The company specializes in the discovery, development, and commercialization of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Corcept's primary focus is on addressing the adverse effects of excess cortisol, which can lead to life-threatening conditions including Cushing's syndrome, various cancers, diabetes, and neurological disorders. The company's flagship product is Korlym (mifepristone), the first FDA-approved oral therapy for treating hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance. With approximately 500 employees, Corcept has developed a large portfolio of proprietary compounds that selectively modulate cortisol effects without compromising progesterone function. The company maintains extensive intellectual property covering its selective cortisol modulators and continues to advance clinical trials for potential treatments of hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.